Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.36 |
| ▸ | CRHBP | P24387 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17064495 | 0.76 | ALDH1A1 (0.43) | MEN1KMT2ALMNAHTTHCAR3 | |
| SCHEMBL17073433 | 0.76 | DHFR (0.40) | MEN1KMT2ALMNAHTTTDP1 | |
| SCHEMBL27758106 | 0.75 | MEN1 (0.44) | MEN1KMT2ALMNAHTTHCAR3 | |
| SCHEMBL18138718 | 0.75 | ALDH1A1 (0.43) | MEN1KMT2ALMNAHTTHCAR3 | |
| SCHEMBL27758119 | 0.75 | MEN1 (0.46) | MEN1KMT2ALMNAHTTTDP1 | |
| SCHEMBL7153294 | 0.74 | DHFR (0.43) | MEN1KMT2AALDH1A1CRHBPCRHR2 | |
| SCHEMBL10790484 | 0.72 | CHRM2 (0.43) | MEN1KMT2ALMNAHTTALDH1A1 | |
| SCHEMBL8812805 | 0.72 | HSD17B10 (0.43) | LMNAHCAR3TDP1ALDH1A1ALDH3A1 | |
| SCHEMBL28497609 | 0.72 | TDP1 (0.54) | MEN1KMT2ALMNAHTTHCAR3 | |
| SCHEMBL17064327 | 0.71 | ALDH1A1 (0.56) | MEN1KMT2ALMNAHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4663636-A2 | TRIFLUOROMETHYL SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BioCryst Pharmaceuticals, Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250270171-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-08-28 | — | — | US | disclosed |
| US-20250257040-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-08-14 | — | — | US | disclosed |
| EP-4180424-B1 | SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2025-06-25 | — | — | EP | disclosed |
| US-12162838-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-12116346-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-10-15 | — | — | US | disclosed |
| CN-113307772-B | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2024-06-28 | — | — | CN | disclosed |
| US-20240150295-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-05-09 | — | — | US | disclosed |
| US-20240150296-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-05-09 | — | — | US | disclosed |
| US-11708333-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-10329260-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180354906-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2018-12-13 | — | — | US | disclosed |
| US-10125102-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180258049-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2018-09-13 | — | — | US | disclosed |
| US-20170073314-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-03-16 | — | — | US | disclosed |
| US-20170073314-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-03-16 | — | — | US | disclosed |
| US-20170073314-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-03-16 | — | — | US | disclosed |
| EP-3113772-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2017-01-11 | — | — | EP | disclosed |
| WO-2015134998-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2015-09-11 | — | — | WO | disclosed |
| WO-2015134998-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2015-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180354906-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK5 | MEN1 519/4885KMT2A 2113/4885LMNA 1126/4885 |
| US-12116346-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | MEN1 407/4885KMT2A 1644/4885LMNA 998/4885 |
| US-20250270171-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | MEN1 407/4885KMT2A 1644/4885LMNA 998/4885 |
| US-20240150296-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | MEN1 407/4885KMT2A 1644/4885LMNA 998/4885 |
| US-10329260-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | MEN1 519/4885KMT2A 2113/4885LMNA 1126/4885 |
| US-10125102-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | MEN1 519/4885KMT2A 2113/4885LMNA 1126/4885 |
| US-20170073314-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK5 | MEN1 519/4885KMT2A 2113/4885LMNA 1126/4885 |
| US-20240150295-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | MEN1 407/4885KMT2A 1644/4885LMNA 998/4885 |
| US-20250257040-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | MEN1 407/4885KMT2A 1644/4885LMNA 998/4885 |
| US-11708333-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | MEN1 501/4885KMT2A 1846/4885LMNA 824/4885 |
| US-20180258049-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK5 | MEN1 519/4885KMT2A 2113/4885LMNA 1126/4885 |
| US-12162838-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | MEN1 407/4885KMT2A 1644/4885LMNA 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.